Alimera Sciences

Alimera Sciences

Alimera Sciences

Biopharmaceutical company that researches, develops and commercializes prescription ophthalmic pharmaceuticals with a focus on the back of the eye, or retina.
Founded
2003
Raised
$61.5M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$26,500,000
Post-IPO equity - 2016
$35,000,000
Post-IPO debt - 2014
Team Size
50+
Employees
$26,500,000 Post-IPO equity
GlobeNewswire News Room

Alimera Sciences Announces Exercise of Underwriters’ Over-Allotment Option and Closing of $26.5 Million Offering of Comm...